Compare ACOG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | ANTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 172.9M |
| IPO Year | 2024 | 2022 |
| Metric | ACOG | ANTX |
|---|---|---|
| Price | $8.80 | $5.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.00 | $2.00 |
| AVG Volume (30 Days) | 153.2K | ★ 198.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.58 | 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,220,275.00 | N/A |
| Revenue This Year | $139.22 | N/A |
| Revenue Next Year | $134.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.50 | $1.00 |
| 52 Week High | $10.14 | $7.19 |
| Indicator | ACOG | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 43.50 |
| Support Level | $7.50 | $3.91 |
| Resistance Level | $9.04 | $5.51 |
| Average True Range (ATR) | 0.51 | 0.34 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 13.91 | 13.68 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.